EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Cellular Immune Response Induced by mRNA Vaccines Against SARS‐CoV‐2

Valentina Tovar iD, Isaura Pilar Sánchez iD, María Teresa Rugeles iD, Natalia Andrea Taborda iD, Juan C Hernandez iD

Immunity, Inflammation and Disease · 2026-03 · 14 (3)

DOI: 10.1002/iid3.70375 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunity, Inflammation and Disease, online erschienen am 11.03.2026. Verfasst von Valentina Tovar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Grupo Inmunovirología, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19, Immunity, Cellular, COVID-19 Vaccines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidad Cooperativa de Colombia, Corporación Universitaria Remington, Universidad de Antioquia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The disease caused by SARS‐CoV‐2 is known as COVID‐19, and it can range from mild symptoms to severe clinical manifestations, including respiratory failure, pneumonia, and organ failure. Since its emergence in 2019, more than 7 million deaths have been reported worldwide. Vaccines have been the most effective strategy for preventing severe illness and death in patients who acquire the infection. Vaccines induce both humoral and cell‐mediated immune responses; the latter is crucial in the immune response against SARS‐CoV‐2, as the effector mechanisms of T‐cells are less affected by the high mutation rate of the virus and prevail through memory phenotypes, ensuring long‐term protection. mRNA vaccines have been primarily used worldwide to control the COVID‐19 pandemic. This platform can protect against different circulating variants and is characterized by generating a robust T‐cell response. This review discusses the immune response of T‐cells induced by mRNA vaccines against SARS‐CoV‐2. It explores their effect on different population groups, including people with special clinical conditions, such as cancer and organ transplant recipients with a compromised immune system.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19Immunity, CellularCOVID-19 VaccinesHumansT-LymphocytesmRNA VaccinesVaccines, SyntheticAnimals

Stichwörter der Autor:innen

COVID‐19SARS‐CoV‐2cancercellular immunitymRNA vaccinesorgan transplant

Substanzen

COVID-19 VaccinesmRNA VaccinesVaccines, Synthetic

Autor:innen und Institutionen

  • Grupo Inmunovirología, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia.
  • Grupo de Investigaciones Biomédicas Uniremington, Programa de Medicina, Facultad de Ciencias de la Salud, Corporación Universitaria Remington, Medellín, Colombia.
  • Infettare, Facultad de Medicina, Universidad Cooperativa de Colombia, Medellín, Colombia.

ORCID-Profile: Valentina Tovar, Isaura Pilar Sánchez, María Teresa Rugeles, Natalia Andrea Taborda, Juan C Hernandez

Förderung

  • Universidad Cooperativa de Colombia
  • Corporación Universitaria Remington
  • Universidad de Antioquia

Zitieren

APA

Tovar, V., Sánchez, I. P., Rugeles, M. T., Taborda, N. A., & Hernandez, J. C. (2026). Cellular Immune Response Induced by mRNA Vaccines Against SARS‐CoV‐2. Immunity, Inflammation and Disease, 14(3). https://doi.org/10.1002/iid3.70375

Vancouver

Tovar V, Sánchez IP, Rugeles MT, Taborda NA, Hernandez JC. Cellular Immune Response Induced by mRNA Vaccines Against SARS‐CoV‐2. Immunity, Inflammation and Disease. 2026;14(3). doi:10.1002/iid3.70375

BibTeX
@article{Tovar2026,
  author = {Tovar, Valentina and Sánchez, Isaura Pilar and Rugeles, María Teresa and Taborda, Natalia Andrea and Hernandez, Juan C},
  title = {Cellular Immune Response Induced by mRNA Vaccines Against SARS‐CoV‐2},
  journal = {Immunity, Inflammation and Disease},
  year = {2026},
  volume = {14},
  number = {3},
  doi = {10.1002/iid3.70375}
}
Kostenlos starten →